Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study

Next Previous
Trial Profile

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylprednisolone (Primary) ; NTx 265 (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Mar 2026 Status changed from suspended to discontinued as the financial support was terminated by the sponsor.
  • 05 Mar 2026 Status changed from recruiting to suspended.
  • 21 Oct 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top